UNIVEST FINANCIAL Corp Sells 125 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

UNIVEST FINANCIAL Corp reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,323 shares of the company’s stock after selling 125 shares during the period. UNIVEST FINANCIAL Corp’s holdings in IDEXX Laboratories were worth $960,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. FSA Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the 3rd quarter worth approximately $25,000. Rialto Wealth Management LLC bought a new position in IDEXX Laboratories in the 4th quarter valued at $30,000. Retirement Wealth Solutions LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $31,000. Kestra Investment Management LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter worth $38,000. Finally, Crews Bank & Trust purchased a new position in shares of IDEXX Laboratories in the 4th quarter worth about $41,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Up 0.0 %

IDXX opened at $417.71 on Thursday. The firm has a market capitalization of $33.86 billion, a P/E ratio of 39.15, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $548.88. The company has a fifty day moving average price of $437.26 and a 200-day moving average price of $443.87. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Morgan Stanley decreased their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Bank of America lifted their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Leerink Partners assumed coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price on the stock. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average target price of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.